|Articles|September 1, 2019
- Pharmaceutical Executive-09-01-2019
- Volume 39
- Issue 9
Pharmaceutical Executive, September 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 6 years ago
Pharm Exec's 18th Annual Industry Auditabout 6 years ago
Product Development: The Optimizer’s Curseabout 6 years ago
Setting Your Launch Pathabout 6 years ago
Pre-launch Prep: The Modern Protocolabout 6 years ago
The Murky Outlook for Generic Drugsabout 6 years ago
Post-Launch Birthday: The Time to Refineabout 6 years ago
Product Launch: Five Paths Forwardabout 6 years ago
Once Upon a Brandabout 6 years ago
Country Report: Chinaabout 6 years ago
Other Products to WatchNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics
2
FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma
3
Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform
4
The Situation We Faced: The Development and Commercialization of MariTide
5
